Sep 08, 2022 / 03:20PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
Gracell therapy company is with us this morning. I'm Yigal Nochomovitz one of the biotech analysts at Citi. And we have from Caribou, Steve Kanner, the CSO and Kevin, welcome both of you. Thank you very much for participating. So since some people may not be super familiar with your platforms and your pipelines, maybe just take just a quick 2 to 3 minutes to just give us an overview of where you are, what are your key assets, where you are in the pipeline or maybe what are the 1 or 2 biggest catalysts coming up for each of you in the next 6 to 12 .
Yili Xie - Gracell Biotechnologies Inc. - CFO
Well, thanks, Yigal, and thanks to Citi for last opportunity to talk about cell therapy and CAR-T. So I'm the CFO of Gracell Bio. In cell therapy, and we have 2 platforms in the CAR-T. The one is on the canoes side, we have the fast CAR, that's the next day manufacturing. And then we also have the allogeneic platform, which we call the Trio CAR that we can talk more about that in terms of our elegant
Gracell Biotechnologies Inc at Citi BioPharma Conference Transcript
Sep 08, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers